As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...

Bristol-Myers Squibb (SMY) stock falls as its Q4 2024 results beat Street forecasts, but its 2025 outlook fell short of ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...

On a per-share basis, the Princeton, New Jersey-based company said it had net income of 4 cents. Earnings, adjusted for non-recurring costs, came to $1.67 per share. The results surpassed Wall Street ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Core to its strategy, Bristol Myers Squibb actively invests in the development of new molecular entities, alongside strategically acquiring companies to amplify its R&D capabilities. This approach ...